Vektor: Enabling Precision and Efficiency in Cardiac Care
In a selective venture capital environment, Sower continues to focus on gaining exposure to companies addressing real-world problems with identifiable paths to scale. Through our relationship with Solas BioVentures, which supports companies like Vektor Medical through continued investments across its funds and related vehicles, Sower participates in select opportunities where technical development is supported by practical application.
This quarter, we highlight Vektor, a medical technology company focused on improving the identification and treatment of heart rhythm disorders. Vektor develops vMap, an FDA-cleared software platform that uses artificial intelligence to help physicians identify the origin of abnormal heart rhythms. The platform uses data from a standard 12-lead ECG, a test commonly used in cardiology care, to generate a full-heart map in under one minute. This information is available to physicians before a procedure begins and is intended to support procedural planning.
vMap is currently in use across multiple electrophysiology labs and is designed to address challenges in accurately identifying arrhythmia sources. By providing information earlier in the care process, the platform may reduce uncertainty during procedures and support more consistent planning.
Cardiac Mapping Approach
Traditional cardiac mapping typically involves invasive catheter-based procedures performed during the intervention itself. These procedures can vary in duration and complexity depending on patient characteristics and physician technique. vMap provides a non-invasive method intended to supplement this process by offering guidance in advance.
Clinical experience reported to date suggests that use of vMap has been associated with reductions in procedure time of approximately 23% and improvements in lab throughput of roughly 20%. These outcomes may allow hospitals to improve operational efficiency while potentially reducing patient procedure duration.
The platform is designed to integrate with existing ablation technologies, including newer approaches such as pulsed field ablation, and does not require additional capital equipment. Vektor holds more than 70 issued patents and over 60 pending patents related to non-invasive cardiac mapping.
Vektor operates within the cardiac mapping and ablation market, which is estimated at approximately $8 billion and is projected to grow to $23 billion by 2030. Market growth is driven by increased diagnosis of heart rhythm disorders, evolving treatment guidelines, and broader adoption of ablation technologies.
To learn more about Vektor Medical please visit: https://www.vektormedical.com/
